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Background
In vitro and in vivo data have suggested that ritonavir/
lopinavir is one of the most potent protease inhibitor
against HIV-2 infection. Nevertheless, only few clinical
reports have been published. So, it seemed to us impor-
tant to report our clinical experience in 9 patients.
Methods
We searched in our database patients with HIV-2 who
have been treated with ritonavir/lopinavir. 9 patients (4
women and 5 men) were identified. Clinical and biologi-
cal evolution was analyzed.
Results
At the time of initiation of lopinavir, median age was 54
(37-66). Median duration of HIV infection was 41,6
months (6-101). Previous median duration of treatment
was 29 months (4-51). No patient was naïve of treat-
ment. The median previous number of regimens
received was 2 (1-2). 5/9 patients were naïve of protease
inhibitors. Initial median CD4 cells were 150 (68-478).
Viral load (VL) was under the limit of detection in 6
cases. Reasons for switching to lopinavir were toxicity or
intolerance (n = 2), absence of efficacy on VL (n = 3) or
inadequacy of previous treatment (n = 4). In all cases,
lopinavir was given in association of 2 NRTIs.
After a median follow-up of 60 months (18-84), no
severe side effect was observed. VL under the limits of
detection was obtained for all patients except for one
patient with a very poor compliance. In this later case,
after switching lopinavir to raltegravir, VL remained
undetectable. CD4 increased in all cases. The median
gain of CD4 from baseline was + 234 (+50 - +472).
Discussion
Because of the very low frequency of the disease in wes-
tern countries, data on the treatment of HIV-2 infection
are uncommon. For these reasons, treatment of HIV-2
patients remains difficult. So, reports on therapeutic
options are very important. Even with a modest number
of patients, we confirmed the excellent long-term effi-
ciency of lopinavir for the treatment of HIV-2 patients.
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